Ras-mediated signaling pathways play a critical role in cellular proliferation and dierentiation. Although it has been demonstrated that Ras interacts with Raf-1 to stimulate the serine/threonine kinase activity of Raf-1, the precise mechanism by which Ras activates Raf-1 remains obscure. To address this question, we developed a cell-free system in which the activated form of H-Ras can induce Raf-1 activation. Using this system, we found the presence of a new protein factor, in cytosolic fractions of both human embryonic kidney 293 cells and rat brain tissues, that is required for Ras-dependent activation of Raf-1. The factor was puri®ed from rat brain cytosols through successive column chromatographies on DEAE Sephacel, SP Sepharose and Sephacryl S-300. The approximate molecular weight of the activator was estimated as 400 000 by gel ®ltration. Its activity was sensitive to heat and trypsin treatments. The puri®ed activator did not contain Src, 14-3-3, protein kinase C, JAK2 or Ksr-1, as judged by immunoblotting. Further characterization of the activator is underway.
Introduction
Ras functions as a key molecule in cellular signal transduction for regulation of proliferation, differentiation and transformation of mammalian cells (Barbacid, 1987; Kaziro et al., 1991; Lowy and Willumsen, 1993) . Upon binding to receptors, growth factors such as epidermal growth factor and platelet-derived growth factor enhance the intrinsic tyrosine kinase activity of receptors, leading to the binding of adaptor proteins to the receptor and translocation of the guanine-nucleotide exchange factor mSos to the plasma membrane. Membrane-recruited mSos, in turn, converts Ras to an active, GTP-bound form (Schlessinger, 1993 ). Activated Ras then interacts with several eector molecules to transmit the signals downstream (Marshall, 1995) .
The most well-characterized eector of Ras is a cytosolic serine/threonine kinase Raf (Avruch et al., 1994; Daum et al., 1994; Morrison and Cutler, 1997) . In mammals, three isoforms ± Raf-1, A-Raf and BRaf ± have been identi®ed and share three conserved regions (CR1, CR2 and CR3). CR3 is the kinase catalytic domain, while CR1 and CR2 comprise an Nterminal regulatory domain. When activated, Raf-1 phosphorylates and activates a dual-speci®city kinase MEK (also known as MAPKK), which in turn phosphorylates and activates mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) (Macdonald et al., 1993; Nishida and Gotoh, 1993) . Activated MAPK then phosphorylates a number of key substrates including various protein kinases, transcription factors and cytoskeletal proteins (Davis, 1993; Seger and Krebs, 1995) .
Although extensive studies have revealed the detailed mechanism of signal transduction both upstream of Ras and downstream of Raf-1, the mechanism by which Ras activates Raf-1 remains obscure. Raf-1 was found to bind speci®cally and with high anity to the GTP-bound form of Ras through its N-terminal portion (Moodie et al., 1993; Van Aelst et al., 1993; Koide et al., 1993; Vojtek et al., 1993; Warne et al., 1993; Zhang et al., 1993) . However, direct interaction between Ras and Raf-1 is in itself insucient to activate Raf-1 (Traverse et al., 1993; Zhang et al., 1993) , indicating that an additional molecule(s) is required for Ras-induced Raf-1 activation. To identify such an additional molecule(s), in this report, we constructed an in vitro reconstitution system for HRas ± induced Raf-1 activation. Using this system, we found that a fraction from anion-exchange chromatography of the cytosol of human embryonic kidney (HEK) 293 cells or rat brain is essential for activation of Raf-1 by Ras. The Ras-dependent Raf-1 activator was puri®ed through several column chromatographies. The properties of the partially puri®ed protein are described.
Results

Activation of Raf-1 by H-Ras in the cell-free system
To study the mechanism of Raf-1 activation by Ras, we constructed a cell-free system in which HRas[G12V] derived from the Sf9 cells activates RafFH (Raf-1 with¯ag-epitope tag and six histidine residues in its C terminus) expressed in HEK293 cells. The cytosolic fraction containing RafFH was prepared from the serum-starved HEK293/RafFH cells, and incubated with the membrane fraction containing Ras[G12V] obtained from the Sf9 cells infected with H-Ras[G12V] baculovirus (see Materials and methods). RafFH was immunoprecipitated with an anti-¯ag antibody and the Raf activity in the precipitate was measured using recombinant MEK and kinase-de®cient MAPK as substrates. It was found that RafFH was strongly activated by Ras[G12V] membrane ( Figure 1 , bar 2). Without the membrane fraction, RafFH displayed only a slight activity (bar 1). Control experiments without the anti-¯ag antibody (bars 3 and 4) showed negligible activity, indicating that the observed Raf activity was due to RafFH and not to the non-speci®c absorption to protein G-Sepharose of endogenous Raf contained in the preparation of Ras[G12V] membrane. Since the membrane fraction prepared from Sf9 cells either uninfected or infected with dominant-negative mutant Ras (Ras[S17N]) baculovirus did not activate RafFH (data not shown), the activation of RafFH was induced by the activated form of Ras.
Existence of Raf-1 activator in cytosolic fraction
Using a cell-free system with COS cells, Stokoe and McCormick (1997) have recently reported that puri®ed Ras activated Raf-1 in the cytosolic fraction, but not puri®ed Raf-1. Similarly, we could not activate immunoprecipitated RafFH by Ras[G12V] membrane (data not shown). These results suggest the possibility that the cytosolic fraction may contain a molecule which is necessary for activation of Raf-1.
To test this possibility, we ®rst separated RafFH cytosol into two fractions. RafFH cytosol was absorbed to a Mono Q column, and the column was eluted ®rst with buer B containing 0.2 M NaCl (0 ± 0.2 M fraction), and then with 0.5 M NaCl (0.2 ± 0.5 M fraction). Immunoblot analysis with the anti-¯ag antibody revealed that RafFH was eluted in the 0.2 ± 0.5 M fraction (data not shown). When this fraction was incubated with Ras[G12V] membrane, activity of RafFH was not increased (Figure 2 , bar 4), whereas in the presence of both the 0 ± 0.2 M and the 0.2 ± 0.5 M fractions, RafFH was strongly activated (bar 6). These results indicate that the 0 ± 0.2 M fraction contained an activator required for the Rasdependent Raf-1 activation (hereafter referred to as à Raf-1 activator').
To examine whether the activator exists also in rat brain, we prepared 0 ± 0.25 M NH 4 Cl fraction from the cytosolic fraction of rat brain using a DEAE Sephacel column. As a source of RafFH, we prepared 0.22 ± 0.4 M NH 4 Cl fraction of a Resource Q column from HEK293/RafFH cytosol and con®rmed by Western blotting analysis that most of RafFH was eluted in this fraction (data not shown). This fraction is referred to as a`RafFH fraction' in the following experiments. As shown in Figure 3 , incubation of RafFH fraction with Ras[G12V] membrane alone failed to activate RafFH (bar 2), while the addition of the 0 ± 0.25 M NH 4 Cl DEAE Sephacel fraction of rat brain cytosols led to a strong activation of RafFH (bar 4). In contrast, neither the¯owthrough fraction nor the 0.25 ± 0.5 M NH 4 Cl DEAE Sephacel fraction of rat brain cytosols showed any Raf-1 activator activity (data not shown), indicating that only the 0 ± 0.25 M NH 4 Cl fraction contained the Raf-1 activator.
Partial puri®cation of Raf-1 activator from rat brain
The cytosolic fraction (S100) from 20 rat brains was chromatographed on a DEAE Sephacel column to obtain the 0 ± 0.25 M NH 4 Cl fraction. The protein was precipitated with 33% saturated ammonium sulfate, and the pellet was dissolved in buer C and subjected to cation-exchange chromatography using SP Sepharose. The activator was eluted in 0.2 ± 0.3 M NH 4 Cl fraction, which was concentrated by Ultrafree 15 and applied to a Sephacryl S-300 column ( Figure 4 ). The fractions (fractions 27 ± 31) containing Raf-1 activator were pooled and used for the following experiments. A summary of puri®cation is shown in Table 1 . About 87-fold puri®cation of Raf-1 activator activity was achieved with the recovery of 17%.
Characterization of partially puri®ed Raf-1 activator
When the partially puri®ed preparation was treated with either heat or trypsin, its Raf-1 activator (Figure 5a ), indicating that the activator is a protein molecule. As judged from the elution position in the gel ®ltration chromatography (Figure 4) , the approximate molecular weight of the activator was estimated as 400 000. Thus, the activator was likely to be a relatively large protein molecule which may consist of multiple subunits. Several proteins including Src, 14-3-3, protein kinase C (PKC), JAK2 and Ksr-1 have been reported as possible Raf-1 activators (Morrison and Cutler, 1997) . The immunoblot analysis with speci®c antibodies against these molecules indicated that they were removed at the early stage of puri®cation and the partially puri®ed activator did not contain any of these molecules to a detectable amount (Figure 6 ). Next, we carried out a kinetic study of Raf-1 activation by the activator fraction. When incubated at 168C, Raf-1 activity increased linearly over a 40 min period and reached a plateau (Figure 5b ). The increase of Raf-1 activity was sigmoidal rather than linear to the amount of Raf-1 activator added to the reaction mixture (Figure 5c ). This may indicate the presence of multiple components, either in the partially puri®ed preparation of Raf-1 activator or in the RafFH fraction.
Discussion
Activation of Raf-1 through Ras appears to be not a simple but a complex process requiring several additional protein molecules. Since the direct interaction between Ras and Raf-1 was by itself not sucient to induce the Raf-1 activation, it has been considered that there may be an additional molecule(s) required for activation. However, in spite of the extensive studies, the putative activator has not been well de®ned. First, the presence of activator(s) in the cytoplasmic membrane was supposed since targeting of Raf-1 to the cytoplasmic membrane by addition of a CAAX motif with the 20 terminal amino acids of KRas induced activation of Raf-1 (Leevers et al., 1994; Stokoe et al., 1994) . A partially puri®ed membrane fraction from v-Ras-transformed NIH3T3 cells was found to increase the kinase activity of Raf-1 in the cell-free system (Dent and Sturgill, 1994) . These results strengthened the idea that the unknown activator molecule(s) may be localized on the cytoplasmic membrane. In accord with this, the membraneassociated tyrosine kinase Src was shown to activate Raf-1 synergistically with Ras both in the whole cell and the cell-free system (Williams et al., 1992; Fabian et al., 1993; Dent and Sturgill, 1994; Marais et al., 1995; Mizutani et al., unpublished) .
On the other hand, Stokoe and McCormick (1997) have more recently reported that, in the membrane fraction prepared from Ras-transformed COS cells, Ras is the only molecule required for the Raf-1 activation, suggesting that the activator molecule(s) may exist in the cytosolic rather than the membrane fraction. Several proteins have so far been reported as possible candidates for the cytosolic Raf-1 activator. For example, 14-3-3 was identi®ed as a molecule that activates Raf-1 in a Ras-dependent manner using a genetic screen with Saccharomyces cerevisiae (Irie et al., 1994) and as a Raf-1 binding protein using yeast twohybrid system (Fantl et al., 1994; Freed et al., 1994) . Furthermore, 14-3-3 has been shown to increase the kinase activity of Raf-1 when introduced into Xenopus oocytes or yeast cells (Fantl et al., 1994; Freed et al., 1994) or in the cell-free system derived from yeast (Irie et al., 1994) . However, since Raf-1 constitutively binds to 14-3-3, regardless of its activated state (Freed et al., 1994) , it is likely that 14-3-3 functions as a structural component of a complex involving Raf-1. PKC is also reported to be a Raf-1 activator, because treatment of cells with phorbol ester leads to activation of Raf-1. PKCa has also been shown to increase the kinase activity of Raf-1 in the cell-free system (Kolch et al., 1993) , although it is not clear whether PKC is involved in the Ras-dependent Raf-1 activation. Ksr-1 was originally identi®ed as a suppressor of abnormal phenotype induced by an activated mutant of Ras in both Drosophila (Therrien et al., 1995) and Caenorhabditis elegans (Kornfeld et al., 1995; Sundaram and Han, 1995) . Since Ksr-1 associates with Raf-1 in a Rasdependent manner (Therrien et al., 1996) , it may also be a candidate for a cytosolic Raf-1 activator.
In the present study, we established a cell-free system in which activation of Raf-1 is induced by the HRas[G12V] ± containing membrane fraction and demonstrated that an H-Ras ± dependent Raf-1 activator exists in the cytosolic fraction. We succeeded in the partial puri®cation of the activator from rat brain cytosols. The activity was precipitated with 33% saturated ammonium sulfate resulting in about eight fold puri®cation (Table  1) . The factor appears to have a relatively high molecular weight, as judged by the elution pro®le of the gel ®ltration chromatography (Figure 4) . The gradient elution from the ion-exchange chromatographies was not successful since the activity was eluted in multiple peaks. These observations suggest that the activator may be a complex consisting of several subunits. Kinetic studies with the partially puri®ed preparation showed that the dependency of Raf-1 activation on the amount of the activator is sigmoidal rather than linear (Figure 5c ). This may suggest the presence of more than one factor either in the activator fraction, Ras[G12V] membrane, or RafFH fraction. We observed that the yield of the activator activity was increased after ion-exchange chromatography with DEAE Sephacel and ammonium sulfate precipitation (Table 1 ). This suggests that some inhibitory molecules against Raf-1 activation may exist in the crude extract.
At present, the mechanism of activation of Raf-1 by the partially puri®ed activator remains unclear. One possibility is that the activator phosphorylates Raf-1 to enhance its kinase activity. When activated by co- expression with Ras and Src, Raf-1 undergoes phosphorylation on Tyr-340 and Tyr-341, and substitution of these residues with Asp increases its basal kinase activity (Fabian et al., 1993) . In addition, treatment of activated Raf-1 with tyrosine phophatase results in the reduced kinase activity (Dent et al., 1995) . Moreover, it was reported that, when coexpressed with Raf-1, Ras can induce tyrosine phosphorylation of Raf-1 by an unknown tyrosine kinase (Marais et al., 1995; Jelinek et al., 1996) . These data indicate the importance of phosphorylation of Raf-1 for its activation. We do not know whether a phosphorylation of Raf-1 is indispensable for Rasinduced activation of Raf-1 in our cell-free system. An alternate possibility is that the activator is not a kinase but binds to Raf-1 in a Ras-dependent manner and induces a conformational change of Raf-1, resulting in the increased catalytic activity of Raf-1. The importance of dimerization of Raf-1 molecules for activation has recently been reported (Farrar et al., 1996; Luo et al., 1996) . The activator may promote the dimerization of Raf-1 in the cytosol. In contrast to Raf-1, B-Raf has been shown to be activated by Ras alone (Yamamori et al., 1995; Kuroda et al., 1996) . It will be of interest to examine whether the activator puri®ed from rat brain has any eect on the activation of B-Raf or A-Raf by Ras[G12V].
The procedure described in the present study resulted in about 87-fold puri®cation over the crude extracts from rat brain with an yield of 17%. However, the preparation still contains several proteins, as judged by the patterns of SDS ± PAGE gel stained with Coomassie Blue (data not shown). Immunoblot analysis with cognate antibodies revealed that the partially puri®ed factor does not contain Src, JAK2, 14-3-3. PKC or Ksr-1 suggesting that the activator may be a novel protein. Further studies are currently underway to clarify the molecular nature of the activator and the mechanism of Raf-1 activation by Ras.
Materials and methods
Materials
Complementary DNA of human H-Ras[G12V] was subcloned into the BamHI sites of a baculovirus transfer vector, pAcYM1 (Matsuura et al., 1987 ) (a kind gift from Yoshiharu Matsuura, National Institute of Health, Japan) to obtain pAcYM1-Ras[G12V]. Plasmid pLNC-Raf-1 : FH6 and bacterial expression system for recombinant histidinetagged Xenopus MEK (His-MEK) and glutathione-S-transferase ± fused kinase-de®cient Xenopus MAPK (GST-kdMAPK) (Kosako et al., 1993) , were kindly given by Martin McMahon (DNAX Research Institute, Palo Alto, CA) and Eisuke Nishida (Kyoto University, Japan), respectively. Antibodies against¯ag epitope (M2), JAK2(06 ± 255), and PKCs(10267 ± 011) were purchased from Eastman Kodak (New Heaven, CT), Upstate Biotechnology (Lake Placid, NY) and Gibco BRL (Gaithersburg, MD), respectively. Anti-Ksr-1 antibody (sc-1837), anti-Src antibody (sc-629) were obtained from Santa Cruz (Santa Cruz, CA). Mono Q and Resource Q columns, protein G-Sepharose, DEAE Sephacel, SP Sepharose Fast Flow and Sephacryl S-300 were obtained from Pharmacia (Uppsala, Sweden). Trypsin and trypsinchymotrypsin inhibitor were from Sigma.
Cell culture HEK293 cells were maintained in Dulbecco's modi®ed Eagle's medium (DMEM, Nissui, Japan) supplemented with 10% fetal bovine serum (FBS) at 378C in atmosphere of 10% CO 2 /90% air. Spodoptera frugiperda (Sf) nine cells were cultured in IPL-41 (Gibco BRL) supplemented with 10% FBS at 268C.
Preparation of membrane and cytosolic fraction
Membrane fraction containing H-Ras[G12V] was prepared using the baculovirus/Sf9 cell system. Sf9 cells were transfected with pAcYM1-Ras[G12V] using the BaculoGold kit (Pharmingen, CA) and baculovirus encoding HRas[G12V] was isolated by published procedures (Summers and Smith, 1987) . Sf9 cells were infected with the isolated baculovirus for 2 days. After harvest, cells were suspended in buer A (20 mM HEPES/NaOH, pH 7.4, 0.25 M sucrose, 10 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 25 mM b-glycerophosphate, 2 mM dithiothreitol (DTT), 20 mg/ml aprotinin, 10 mg/ml leupeptin and 10 mg/ml pepstatin A), homogenized with a PotterElvehjem homogenizer, and subjected to centrifugation at 15 000 g to remove nuclei and unbroken cells. The supernatant was then centrifuged at 100 000 g for 1 h. The pellet (P100) was resuspended in buer A and used as a`Ras[G12V] membrane'.
For preparation of cytosol containing RafFH (human Raf-1 with¯ag epitope and six histidine residues in its C terminus), we established a stable HEK293 transfectant, in which RafFH is constitutively expressed. HEK293 cells were transfected with pLNC-Raf-1 : FH6 by calcium phosphate coprecipitation method and several transfectants were isolated using G418 (1 mg/ml). After Western blotting analysis with the anti-¯ag antibody, a clone that exhibited the highest expression level of RafFH was chosen and designated as HEK293/RafFH. HEK293/RafFH cells were cultured till they reached con¯uence and were starved for 1 day in DMEM containing 1 mg/ml bovine serum albumin. Cells were harvested and homogenized in buer A without sucrose and subjected to centrifugation at 100 000 g for 1 h. The supernatant (S100) was used as a`RafFH cytosol'.
Assay for Raf-1 activator
Sample was mixed with RafFH fraction and Ras[G12V] membrane, and incubated at 168C for 30 min. Reaction was terminated by addition of Triton X-100 at a ®nal concentration of 0.5%. Solubilized fractions were subjected to immunoprecipitation with the anti-¯ag antibody and protein G-Sepharose. Kinase activity of RafFH in the precipitate was assayed as previously described (Miyake et al., 1996) . Brie¯y, the immunoprecipitate was incubated at 308C for 20 min with recombinant His-MEK and GST-kdMAPK in the presence of [g-32 P]ATP. The reaction was stopped by boiling in the sample buer for SDS ± PAGE and the sample was resolved by SDS ± PAGE. The radioactivity incorporated into GST ± kdMAPK was measured either by an image analyser (BAS2000, FUJI) or by an scintillation counter (LS6500, Beckman).
Puri®cation of Raf-1 activator
Brains of 20 adult Wistar rats were homogenized in 150 ml of buer B (20 mM HEPES/NaOH, pH 7.4, 5 mM MgCl 2 , 1 mM DTT, 1 mM EDTA, 10 mM NaF, 25 mM bglycerophosphate) supplemented with 20 mg/ml aprotinin, 10 mg/ml leupeptin and 10 mg/ml pepstatin A. The lysate was centrifuged at 100 000 g for 1 h and the supernatant (131 ml, 891 mg of protein) was absorbed to a DEAE Sephacel column (2.5616.5 cm). After washing with buer B, proteins were eluted with buer B containing 0.25 M NH 4 Cl and the fractions that exhibited Raf-1 activator activity (120 ml, 468 mg) were collected, and then mixed with 280 ml of buer B, 100 ml of 50% glycerol and 98 g of ammonium sulfate (33% saturated ammonium sulfate precipitation). After centrifugation, the pellet was dissolved in 150 ml of buer C (25 mM MES/NaOH, pH 6.1, 2 mM MgCl 2 , 0.5 mM DTT) and soluble proteins (94.5 mg) were applied to an SP Sepharose Fast Flow column (1.568 cm). The column was washed with buer C and proteins were eluted by a step to 0.2 M, 0.3 M and 0.5 M NH 4 Cl. Fractions containing Raf-1 activator activity (25 ml, 6.3 mg) were pooled and concentrated with Ultrafree 15 (Millipore). The concentrated fraction was applied to a Sephacryl S-300 column (1.5685 cm) and isocratic elution was performed with buer B containing 25 mM NH 4 Cl. Fractions with Raf-1 activator activity (7.5 ml, 1.7 mg) were collected and used as an`activator fraction'. Protein concentration in each fraction was estimated by the Bradford method.
